Survey shows note-takers are split on their best Obsidian alternative
Obsidian is a popular note-taking app that frequently attracts the praises of privacy enthusiasts. But its learning curve and the focus on Markdown mean that many note-taking aficionados who have tried the app have switched over to other options.
My colleague Mitja wrote about some of the best Obsidian alternatives out there, including Notion, Capacities, Anytype, Google Keep, and some other options. We polled readers on which ones they thought was the best choice — but instead of a resounding winner, the results were relatively close.
Which is the best Obsidian alternative in your opinion?
Based on the votes of just over 2,600 readers, Notion led the poll as the favorite alternative for Obsidian. The note-taking app, known for its free cloud syncing and powerful databases, received 23.72% of the votes. However, results were closer than expected. Not far off was Capacities in second place, which received 22.34% of the votes.
Like Obsidian, both of these alternatives take a while to learn. Notion is packed with features and while I personally use the app, I've found that I have to get to grips with its features in small doses. Meanwhile Capacities also offers a blend of productivity features, including a calendar and an AI assistant.
There's also Anytype, a no-code, offline-first solution that landed in third place with 19.97% of the votes. Despite placing third, it is actually one of the more direct competitors to Obsidian due to its focus on privacy. It's offline-first approach will appeal to those who want to keep their notes on their device without syncing to the web.
So what about those who like simpler solutions? That's where Google Keep comes in. The app received 18.9% of the votes, despite its more limited scope and features. Over 9% of respondents voted for the umbrella of 'other' apps, while 5.28% voted for Evernote.
It looks like the choice for the top Obsidian alternative is hotly contended, which makes sense since people have different note-taking styles and priorities. And sometimes you have to actually combine a few services to really hit that sweet spot for productivity.
Follow
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
30 minutes ago
- Yahoo
Intel Rallies Despite Fitch Downgrade
Intel (NASDAQ:INTC) got a surprise downgrade from Fitch this week, yet its stock popped about 3.6% anyway. The agency dialed down Intel's long-term credit rating from BBB+ to BBB, pointing to a tougher demand backdrop and the need for debt reduction and stronger product ramps over the next year or two. Short-term ratings stayed at F2, so it's not all doom and gloom. Warning! GuruFocus has detected 6 Warning Signs with INTC. At the same time, Intel's next-gen 18A process is acting up. Early reports suggest Panther Lake chips have roughly three times the defect rate they should, and volume ramps are lagging. That's a headache so close to the planned Q4 launch, especially when smooth ramp-up was supposed to prove we're past the worst of manufacturing woes. Still, investors seem to be looking past the short-term noise. Maybe a rebound in PC and data-center spendingor a clean bill of health at the August 12 bond covenant updatewill do the trick. The real verdict, though, will come with Q3 production progress and any signs that Panther Lake irons out its kinks. This article first appeared on GuruFocus.
Yahoo
30 minutes ago
- Yahoo
Recursion Sets $100 Million Partnership Goal by 202
Recursion (NASDAQ:RXRX) just laid out a roadmap that balances science and cash, and it looks promising. CEO Christopher Gibson talked up how the Exscientia tech and the Boltz-2 partnership with MIT and Nvidia have supercharged their end-to-end platformfrom pinpointing targets to simulating trials. That boost in efficiency shines through in their finances. Warning! GuruFocus has detected 6 Warning Signs with RXRX. CFO Ben Taylor confirmed they finished Q2 with $533 M in the bank and expect to keep burn under $390 M next year. Even better, they're targeting over $100 M in partnership inflows by the end of 2026, which should carry them all the way through Q4 2027 without needing extra financing. On the science side, six internal programs are nearing key milestones. Oncology dose-escalation data should roll in by year-end and rare-disease updates are due early next year. The ClinTech AI platform now promises roughly 50 % faster enrollment projections, and they've hit a fourth Sanofi milestone while rolling out neuronal phenomaps with Roche and Genentech. This article first appeared on GuruFocus.
Bloomberg
30 minutes ago
- Bloomberg
OpenAI in Talks for Share Sale Valuing Startup at $500 Billion
OpenAI is in early talks about a potential secondary sale of stock for current and former employees at a valuation of about $500 billion, people briefed on the investment discussions said, marking an enormous gain in value for the artificial intelligence leader. The company is targeting a stock sale in the billions of dollars, the people said, asking to remain anonymous because they weren't authorized to discuss the matter publicly. Existing investors including Thrive Capital have approached OpenAI about buying some of the employee shares, the people said.
